The dose escalation portion of the ongoing ANTLER phase I trial showed positive long-term follow-up clinical data for CB-010, an allogeneic anti-CD19 CAR-T cell therapy, in the treatment of relapsed or refractory B cell non-Hodgkin lymphoma.
The phase III frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi/Minjuvi), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma or high-grade B-cell lymphoma, has produced positive results.
